Guizhou Sanli Pharmaceutical Co Ltd (603439) — Cash Flow-to-Debt Ratio
Guizhou Sanli Pharmaceutical Co Ltd (603439) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥33.19 Million could theoretically repay 0% of its total liabilities (CN¥1.30 Billion) in one year. See Guizhou Sanli Pharmaceutical Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Guizhou Sanli Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Guizhou Sanli Pharmaceutical Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see Guizhou Sanli Pharmaceutical Co Ltd operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Guizhou Sanli Pharmaceutical Co Ltd. Check Guizhou Sanli Pharmaceutical Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | CN¥107.07 Million | CN¥1.60 Billion | ▼ -70.7% |
| 2023 | 0.23x | CN¥276.70 Million | CN¥1.21 Billion | ▼ -54.9% |
| 2022 | 0.51x | CN¥293.29 Million | CN¥578.40 Million | ▲ +22.0% |
| 2021 | 0.42x | CN¥155.04 Million | CN¥372.93 Million | ▲ +82.0% |
| 2020 | 0.23x | CN¥63.25 Million | CN¥276.91 Million | ▼ -84.3% |
| 2019 | 1.46x | CN¥116.24 Million | CN¥79.72 Million | ▲ +13.6% |
| 2018 | 1.28x | CN¥75.35 Million | CN¥58.69 Million | ▲ +105.7% |
| 2017 | 0.62x | CN¥57.47 Million | CN¥92.07 Million | ▲ +55.5% |
| 2016 | 0.40x | CN¥35.10 Million | CN¥87.44 Million | ▲ +3.9% |
| 2015 | 0.39x | CN¥33.28 Million | CN¥86.14 Million | ▲ +9476.2% |
| 2014 | 0.00x | CN¥563.46K | CN¥139.67 Million | ▼ -98.2% |
| 2013 | 0.23x | CN¥30.09 Million | CN¥130.52 Million | — |